LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC)

R.S. Finn, Masatoshi Kudo, Philippe Merle, Tim Meyer, S. Qin, M. Ikeda, R. Xu, Julien Edeline, B-Y. Ryoo, Z. Ren, Ann‐Lii Cheng, P.R. Galle, S. Kaneko, H. Kumada, A. Wang, K. Mody, L. Dubrovsky, A.B. Siegel, J. Llovet